A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
Key facts
- Who runs it
- Beam Therapeutics Inc.
- Where
- Ireland and Netherlands2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 34 people, planned
- Started
- 28 Sept 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional
- Record updated
- 28 July 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 134 criteriaShow less
Who can take part
- Part A: Males or females 18–70 years of age inclusive at the time of consent
- Part A: Evidence of emphysema on a historic CT scan or a DLCO ≤70% of the predicted value (corrected for hemoglobin) at screening. (PFTs obtained within 1 year of signing the ICF may be used for eligibility.)
- Part A: Willingness to abstain from alcohol use, herbal supplements, and daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) and to not engage in strenuous exercise beyond their typical routine from start of screening period through 28 days post IMP administration
- Part A: Able to understand the study and provide informed consent
- Part A: Willingness to participate in this study and a LTFU study with the understanding that the total study participation is 15 years
- Part A: Women of childbearing potential (WoCBP; defined in Appendix 1) must be willing to use highly effective contraception (defined in Appendix 1) from the signing of the ICF through at least 6 months after administration of any dose of BEAM-302. WoCBP must be willing to refrain from donating eggs for a period of 6 months after any administration of any dose of BEAM-302. Males must be willing to use highly effective contraception and to refrain from donating sperm for a period of at least 4 months after any administration of BEAM-302. In addition, males with female partners who are WoCBP must agree to inform their partners to use highly effective contraception for a period of at least 4 months after any administration of BEAM-302 to the male
- Part B: 11 Patients receiving augmentation therapy must be willing to washout augmentation therapy for at least 25 days prior to signing the ICF and for the length of the study (unless clinically indicated per Section 6.5.1)
- Part A: Willingness to not use any investigational product for the duration of the study
- Part B: 1. Males or females 18 – 70 years of age inclusive at the time of consent
- Part B: 2. Diagnosis of AATD and homozygous for the PiZ mutation (confirmed by genetic testing)
- Part B: 3. Clinical diagnosis of AATD-related liver disease along with evidence of METAVIR F1, F2, or F3 liver fibrosis and pathology consistent with AATD-related liver disease (eg, evidence of periodic acid Schiff stain with diastase globules) based on a central or local read of a baseline liver biopsy during the screening period or a histological diagnosis made no more than 6 months before enrollment and stage confirmed by central or local read
- Part B: 7. WoCBP (defined in Appendix 1) must be willing to use highly effective contraception (defined in Appendix 1) from the signing of the ICF through at least 6 months after administration of any dose of BEAM-302. WoCBP must be willing to refrain from donating eggs for a period of 6 months after any administration of any dose of BEAM-302. Males must be willing to use highly effective contraception and to refrain from donating sperm for a period of at least 4 months after any administration of BEAM-302. In addition, males with female partners who are WoCBP must agree to inform their partners to use highly effective contraception for a period of at least 4 months after any administration of BEAM-302 to the male
- Part B: 4. A postbronchodilator FEV1 ≥40% of predicted at screening. (PFTs obtained within 1 year of signing the ICF may be used for eligibility.)
- Part B: 5. Willingness to abstain from alcohol use, herbal medications, and daily use of NSAIDs and to not engage in strenuous exercise beyond their typical routine from start of screening period through 28 days post IMP administration
- Part B: 6. Willingness to participate in this study and LTFU study with the understanding that the total study participation is 15 years
- Part C: Males or females 18-75 years of age inclusive at the time of consent
- Part C: Diagnosis of AATD and homozygous for the PiZ mutation (confirmed by genetic testing)
- Part C: Patients receiving augmentation therapy must be willing to washout augmentation therapy for at least 25 days prior to signing the ICF and for the length of the study (unless clinically indicated per Section 6.5.1)
- Part C: A postbronchodilator FEV1 ≥30% of predicted. (PFTs obtained within 1 year of signing the ICF may be used for eligibility.)
- Part C: Evidence of emphysema on prior chest imaging or chest imaging done at screening if no prior imaging is available
- Part C: Liver stiffness <12 kPa by FibroScan or VCTE equivalent
- Part C: Willingness to participate in this study and an LTFU study with the understanding that the total study participation is 15 years
- Part B: 8. Able to understand the study and provide informed consent
- Part C: WoCBP (defined in Appendix 1) must be willing to use highly effective contraception (defined in Appendix 1) from the signing of the ICF through at least 6 months after administration of any dose of BEAM-302. WoCBP must be willing to refrain from donating eggs for a period of 6 months after any administration of any dose of BEAM-302. Males must be willing to use highly effective contraception and to refrain from donating sperm for a period of at least 4 months after any administration of BEAM-302. In addition, males with female partners who are WoCBP must agree to inform their partners to use highly effective contraception for a period of at least 4 months after any administration of BEAM-302 to the male
- Part C: Able to understand the study and provide informed consent
- Part C: Willingness to not use any investigational product for the duration of the study
- Part A: Diagnosis of AATD and homozygous for the PiZ mutation (confirmed by genetic testing)
- Part B: 9. FibroScan ≤12 kPa
- Part B: 10. Willingness to not use any investigational product for the duration of the study
- Part A: Blood total AAT level <11 μM or equivalent protein in mg/dL
- Part A: Patients receiving augmentation therapy in regions where augmentation is not standard of care (SoC) must be willing to washout augmentation therapy for at least 25 days prior to signing the ICF and for the length of the study (unless clinically indicated per Section 6.5.1)
- Part A: A postbronchodilator FEV1 ≥40% (Phase 1) or ≥35% (Phase 2) of predicted and an FEV1/FVC <70% at screening. (PFTs obtained within 1 year of signing the ICF may be used for eligibility.)
Who cannot take part
- Part A: Lung or liver transplant or on waiting list for lung or liver transplant or status post lung volume reduction via surgery or via valve replacement
- Part C: Prior IV LNP therapy unless case discussed with the medical monitor
- Part C: Inability to tolerate short-term steroids (ie, as outlined in Section 6.2.1 related to premedications)
- Part B: 1. Lung or liver transplant or on waiting list for lung or liver transplant or status post lung volume reduction via surgery or via valve replacement
- Part B: 2. Current or recent smoking history (regular smoking within 12 months prior to signing the ICF) or not willing to abstain from smoking (including vaporizers/e-cigarettes, marijuana) for the duration of the study
- Part A: Prior medically significant vaccine-related reaction (eg, severe hypersensitivity, myocarditis) to an LNP-based product (eg, mRNA-based COVID vaccinations)
- Part A: Current illicit drug use
- Part A: Use of any investigational product within 30 days (or 5 half-lives, whichever is longer) prior to enrollment
- Part B: 14. Previous diagnosis of liver cirrhosis or complications of cirrhosis (eg, varices, ascites, hepatic encephalopathy)
- Part B: 17. Current illicit drug use
- Part B: 20. Active COVID infection as defined as clinical symptoms plus antigen test positivity or positive PCR test within 7 days prior to consent. (Must be symptom free and PCR negative before joining the study.)
- Part B: 21. Previous treatment with any cell, gene, or viral vector-derived experimental therapy
- Part B: 22. Received an LNP treatment (eg, LNP mRNA-based COVID vaccinations) in the 1 month prior to enrollment
- Part B: 23. Prior medically significant vaccine-related reaction (eg, severe hypersensitivity, myocarditis) to an LNP-based product (eg, mRNA-based COVID vaccinations)
- Part B: 24. Use of any investigational product within 30 days (or 5 half-lives, whichever is longer) prior to enrollment
- Part B: 25. Initiation or increase in the dose of a medication that, in the judgment of the investigator, has known potential risk of increasing LFTs (eg, statins, ACE inhibitors, and antifungals) within 5 weeks prior to screening through the completion of the 28-day DLT period
- Part B: 26. Use of systemic steroids above a stable dose equivalent to 10 mg/day daily of prednisone within the 5 weeks prior to screening or during the screening period
- Part A: Initiation or increase in the dose of a medication that, in the judgment of the investigator, has known potential risk of increasing liver function tests (LFTs; eg, statins, ACE inhibitors, and antifungals) within 5 weeks prior to screening through the completion of the 28-day DLT period
- Part A: Current or recent smoking history (regular smoking within 12 months prior to signing the informed consent form [ICF]) or not willing to abstain from smoking (including vaporizers/e-cigarettes, marijuana) for the duration of the study
- Part A: Prior IV LNP therapy unless case discussed with the medical monitor
- Part A: Inability to tolerate short-term steroids (ie, as outlined in Section 6.2.1 related to premedications)
- Part A: Use of systemic steroids above a stable dose equivalent to 10 mg/day daily of prednisone within the 5 weeks prior to screening or during the screening period
- Part B: 36. Prior IV LNP therapy unless case discussed with the medical monitor
- Part B. 37. Inability to tolerate short-term steroids (ie, as outlined in Section 6.2.1 related to premedications)
- Part A: Active COVID infection as defined as clinical symptoms plus antigen test positivity or positive PCR test within 7 days prior to consent. (Must be symptom free and PCR negative before joining the study.)
- Part A: Previous treatment with any cell, gene, or viral vector-derived experimental therapy
- Part A: Received an LNP treatment (eg, LNP mRNA-based COVID vaccinations) in the 1 month prior to enrollment
- Part C: Lung or liver transplant or on waiting list for lung or liver transplant or status post lung volume reduction via surgery or via valve replacement
- Part C: Current or recent smoking history (regular smoking within 12 months prior to signing the ICF) or not willing to abstain from smoking (including vaporizers/e-cigarettes, marijuana) for the duration of the study
- Part C: Current illicit drug use
- Part C: Positive serology for HIV (HIV-1 or HIV-2). (Note: This criterion does not apply to patients who have received effective HIV therapy and have no detectable viral load by PCR.)
- Part C: Active COVID infection as defined as clinical symptoms plus antigen test positivity or positive PCR test within 7 days prior to consent. (Must be symptom free and antigen test or PCR negative before joining the study.)
- Part C: Previous treatment with any cell, gene, or viral vector-derived experimental therapy
- Part C: Received an LNP treatment (eg, LNP mRNA-based COVID vaccinations) in the 1 month prior to enrollment
- Part C: Prior medically significant vaccine-related reaction (eg, severe hypersensitivity, myocarditis) to an LNP-based product (eg, mRNA-based COVID vaccinations)
- Part C: Use of any investigational product within 30 days (or 5 half-lives, whichever is longer) prior to enrollment. Initiation or increase in the dose of a medication that, in the judgment of the investigator, has known potential risk of increasing LFTs (eg, statins, ACE inhibitors, and antifungals) within 5 weeks prior to screening through Day 28
- Part C: Use of systemic steroids above a stable dose equivalent to 10 mg/day daily of prednisone within the 5 weeks prior to screening or during the screening period
- Part A: Malignancy within 3 years except for basal or squamous cell carcinoma or carcinoma in situ of the cervix that has been successfully treated
- Part A: Has a known history of alcohol abuse or daily heavy alcohol consumption (females: more than 14 units of alcohol per week; males: more than 21 units of alcohol per week [unit: 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer])
- Part A: Clinical evidence of severe bronchiectasis as per the discretion of the investigator (eg, excessive sputum production or recurrent infections requiring antibiotic use [>4x/year])
- Part B: 3. Clinical evidence of severe bronchiectasis as per the discretion of the investigator (eg, excessive sputum production or recurrent infections requiring antibiotic use [>4x/year])
- Part B: 11. Seropositive for hepatitis B (positive surface Ag)
- Part B: 12. Active hepatitis C by HCV antibody. If HCV antibody positive, must be HCV RNA PCR negative
- Part B: 16. Has a known history of alcohol abuse or daily heavy alcohol consumption (females: more than 14 units of alcohol per week; males: more than 21 units of alcohol per week [unit: 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer])
- Part A: Positive serology for human immunodeficiency virus (HIV) (HIV-1 or HIV-2)
- Part B: 18. Positive serology for HIV (HIV-1 or HIV-2)
- Part B: 28. Known allergies to any component of BEAM-302
- Part B: 29. Contraindication to corticosteroid use or conditions that could worsen in the presence of corticosteroids as assessed and determined by the investigator
- Part B: 31. Malignancy within 3 years except for basal or squamous cell carcinoma or carcinoma in situ of the cervix that has been successfully treated
- Part B: 34. Active hepatitis A (positive for total anti-HAV and positive for anti-HAV IgM)
- Part C: Clinical evidence of severe bronchiectasis as per the discretion of the investigator (eg, excessive sputum production or recurrent infections requiring antibiotic use [>4 ×/year])
- Part C: Finding on liver ultrasound or other imaging that would indicate evidence of malignancy or cirrhosis or would preclude a safe biopsy at the discretion of the investigator (for the subset of patients who undergo liver biopsy)
- Part C: Known history of liver cirrhosis or complications of cirrhosis (eg, varices, ascites, hepatic encephalopathy)
- Part C: Seropositive for hepatitis B (positive surface Ag)
- Part A: Known allergies to any component of BEAM-302
- Part C: Active hepatitis C by HCV antibody. If HCV antibody positive, must be HCV RNA PCR negative
- Part C: Active hepatitis A (positive for total anti-HAV and positive for anti-HAV IgM)
- Part C: Has a known history of alcohol abuse or daily heavy alcohol consumption (females: more than 14 units of alcohol per week; males: more than 21 units of alcohol per week [unit: 1 glass of wine (125 mL) = 1 measure of spirits = 1/2 pint of beer])
- Part A: Contraindication to short-term corticosteroid use or conditions that could worsen in the presence of corticosteroids as assessed and determined by the investigator
- Part C: Known allergies to any component of BEAM-302
- Part C: Contraindication to short-term corticosteroid use or conditions that could worsen in the presence of corticosteroids as assessed and determined by the investigator
- Part C: Malignancy within 3 years except for basal or squamous cell carcinoma or carcinoma in situ of the cervix that has been successfully treated
- Part A: Serious intercurrent illness, infectious disease, abnormal laboratory result at screening, or medical condition including malignancy or extenuating circumstances that, in the opinion of the investigator, could impair the assessment of safety results (eg, past malignancy that was treated but had significant risk recurrence) or preclude compliance with the study
- Part B: 4. INR ≥1.2 at screening. If deemed appropriate by the investigator and/or prescribing physician, the patient may stop taking anticoagulants for an appropriate washout period and (if indicated) reversal with vitamin K and a repeat INR within <1.2 would be acceptable
- Part B: 8. Total bilirubin levels >ULN; if documented Gilbert’s Syndrome, total bilirubin >2 × ULN
- Part B: 9. ALT and AST >1.5X ULN
- Part B: 10. eGFR <60 mL/min by CKD-EPI equation (Miller, 2022)
- Part B: 13. Symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction <40%, transient ischemic attack, or cerebrovascular accident) within 6 months prior to screening
- Part B: 15. A history of torsades de pointes, ventricular rhythm disturbances (eg, ventricular tachycardia or fibrillation), heart block (excluding first-degree block), congenital long QT syndrome, new ST segment elevation or depression or new Q wave on ECG, or QTcF >450 msec
- Part B: 19. ANC <1500 cells/mm3 OR platelet count <150,000 cells/mm3 OR hemoglobin <10 g/dL for males or <9 g/dL for females
- Part A: Estimated glomerular filtration rate (eGFR) <60 mL/min by CKD-EPI equation (Miller, 2022)
- Patt B: 27. Positive serum pregnancy test or breastfeeding at screening (female participants)
- Part B: 32. Serious intercurrent illness, infectious disease, abnormal laboratory result at screening, or medical condition including malignancy or extenuating circumstances that, in the opinion of the investigator, could impair the assessment of safety results (eg, past malignancy that was treated but had significant risk recurrence) or preclude compliance with the study
- Part A: Liver disease with any of the following: o FibroScan liver stiffness measurement ≥7.5 kilopascals (kPa). (For sites without access to FibroScan, APRI >0.5 can be used as a surrogate exclusion criterion [Yilmaz, 2011]. o Known history of liver cirrhosis or complications of cirrhosis (eg, varices, ascites, hepatic encephalopathy). o Presence of ≥F2 liver fibrosis if a patient has previously had a liver biopsy. o Have ALT or AST > upper limit of normal (ULN). o Total bilirubin levels > ULN; if documented Gilbert’s Syndrome, total bilirubin >2 × ULN. o INR ≥1.2 at screening. If deemed appropriate by the investigator and/or prescribing physician, the patient may stop taking anticoagulants for an appropriate washout period or reversal with vitamin K and if indicated, a repeat INR within <1.2 would be acceptable. o Seropositive for hepatitis B (positive surface Ag). o Active hepatitis C by hepatitis C virus (HCV) antibody. If HCV antibody positive, must be HCV RNA polymerase chain reaction (PCR) negative.o Active hepatitis A (positive for total anti-HAV and positive for anti-HAV IgM)
- Part A: Symptomatic heart failure (≥Class II per New York Heart Association guidelines with confirmed cardiac etiology), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction <40%, transient ischemic attack, or cerebrovascular accident) within 6 months prior to screening
- Part A: A history of torsades de pointes, ventricular rhythm disturbances (eg, ventricular tachycardia or fibrillation), heart block (excluding first-degree block), congenital long QT syndrome, new ST segment elevation or depression or new Q wave on electrocardiogram (ECG), or QT interval corrected using Fridericia’s method (QTcF) >450 msec
- Part A: Absolute neutrophil count (ANC) <1500 cells/mm3 OR platelet count <150,000 cells/mm3 OR hemoglobin <10 g/dL for males or <9 g/dL for females
- Part A: Positive serum pregnancy test or breastfeeding at screening (WoCBP)
- Part C: Have ALT or AST >2 × ULN
- Part C: Total bilirubin levels >ULN; if documented Gilbert’s Syndrome, total bilirubin >2 × ULN
- Part C: INR ≥1.2 at screening that is attributed to underlying liver disease
- Part C: Symptomatic heart failure (≥Class II per New York Heart Association guidelines with confirmed cardiac etiology), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction <40%, transient ischemic attack, or cerebrovascular accident) within 6 months prior to screening
- Part C: eGFR <45 mL/min by CKD-EPI equation (Miller, 2022)
- Part C: ANC <1500 cells/mm3 OR platelet count <150,000 cells/mm3 OR hemoglobin <10g/dL for males or <9 g/dL for females
- Part C: Positive serum pregnancy test or breastfeeding at screening (WoCBP)
- Part C: Serious intercurrent illness, infectious disease, abnormal laboratory result at screening, or medical condition including malignancy or extenuating circumstances that, in the opinion of the investigator, could impair the assessment of safety results (eg, past malignancy that was treated but had significant risk recurrence) or preclude compliance with the study
- Part A: Unwilling or unable to comply with protocol-required visit schedule and visit requirements or provide written informed consent
- Part C: In Ireland, the Netherlands, and Australia only: WoCBP (defined in Appendix 1)
- Part B: 5. Finding on ultrasound or other that would preclude a safe biopsy at the discretion of the investigator
- Part B: 6. COPD exacerbation (defined in Appendix 2) within 6 weeks of signing informed consent
- Part B: 7. On long-term oxygen (ie, requiring continuous oxygen for everyday activities)
- Part A: On long-term oxygen (ie, requiring continuous oxygen for everyday activities)
- Part A: COPD exacerbation (defined in Appendix 2) within 6 weeks of signing informed consent
- Part A: Body mass index >30
- Part B: 30. Unwilling or unable to comply with protocol-required visit schedule and visit requirements or provide written informed consent
- Part A: In Ireland, the Netherlands, and Australia only: WoCBP (defined in Appendix 1)
- Part B: 33. In Ireland, the Netherlands, and Australia only: WoCBP (defined in Appendix 1)
- Part B: 35. BMI >30 for patients in Phase 1; BMI >40 for patients in Phase 2
- Part C: COPD exacerbation (defined in Appendix 2) within 6 weeks of signing informed consent
- Part C: On long-term oxygen (ie, requiring continuous oxygen for everyday activities) unless the oxygen is required because the patient lives in a high-altitude environment and there is documentation that oxygen would not be required at sea-level
- Part C: BMI >40
- Part C: Unwilling or unable to comply with protocol-required visit schedule and visit requirements or provide written informed consent
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Phase 1 (Dose Exploration) Primary Objective: • To evaluate the safety and tolerability of BEAM-302 in patients with AATD-associated lung and/or liver disease and to determine the optimal biological dose (OBD). Phase 2 (Dose Expansion) Primary Objective • To evaluate the efficacy as reflected by the pharmacodynamic (PD) activity of BEAM-302 in patients with AATD-associated lung and/or liver disease to further evaluate the optimal biological dose (OBD) Phase 2 (Pivotal Cohort) Primary Objective • To demonstrate the efficacy of BEAM-302 in patients with AATD-associated lung disease with or without liver disease
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2023-509256-34-00, who can take part
- Record updated
- 28 July 2026